Jacobs Levy Equity Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Jacobs Levy Equity Management’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-544,238	Closed	-$236K	–	1075
2022 Q3	$236K	Buy	+544,238	New	+$408K	﹤0.01%	920
2022 Q1	–	Sell	-12,771	Closed	-$124K	–	1115
2021 Q4	$124K	Sell	12,771 -13,210	-51%	-$183K	﹤0.01%	953
2021 Q3	$465K	Hold	25,981	–	–	﹤0.01%	868
2021 Q2	$634K	Sell	25,981 -12,565	-33%	-$314K	﹤0.01%	824
2021 Q1	$1.02M	Sell	38,546 -356,363	-90%	-$5.21M	0.01%	733
2020 Q4	$3M	Sell	394,909 -7,646	-2%	-$45.4K	0.03%	496
2020 Q3	$2.02M	Buy	402,555 +30,690	+8%	+$163K	0.02%	518
2020 Q2	$2.22M	Buy	+371,865	New	+$2.2M	0.02%	515

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's RUBY Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 544,238 shares — an estimated $236K sold.

Jacobs Levy Equity Management first reported a position in RUBY in Q2 2020 and held it in 8 quarters. The position peaked at $3M in Q4 2020. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

Jacobs Levy Equity Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 544,238 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $236K.
Jacobs Levy Equity Management first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 8 quarters.
Jacobs Levy Equity Management's Rubius Therapeutics, Inc position peaked at $3M in Q4 2020.
42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.